Gene-edited pig kidney works in a human for a record 271 days
A gene-edited pig kidney functioned in a person for 271 days, a xenotransplant record. A new review covers why it worked, why it failed, and what comes next.
Résumé
A new review examines the longest-functioning pig-to-human kidney transplant to date. The organ came from an eGenesis pig carrying 69 edits: three sugar-antigen knockouts, seven human transgenes, and inactivation of porcine retroviruses. It worked for 271 days before being removed because of persistent proteinuria. The authors credit multi-gene editing and a tailored immunosuppression regimen for preventing hyperacute rejection and early graft loss. They attribute the eventual decline to chronic antibody-mediated rejection and thrombotic microangiopathy, patterns also seen in monkeys. A Chinese patient with a 6-gene-edited pig kidney has reached about eight months of function. The FDA has approved larger trials. Open questions remain about infection risk, long-term rejection, and how many edits are actually needed.
Résumé détaillé
Thousands of people with kidney failure wait years for a donor organ, and many never receive one. Pig-to-human kidney transplantation (xenotransplantation) has been proposed as a solution for decades, but immune rejection and clotting problems have limited it. This review by Tao and Zhou describes the longest human pig-kidney function reported so far and what it suggests about the field.
The review is a narrative commentary on a single clinical case, with context from other recent cases and from non-human primate studies. It reports no new trial data. The donor was an eGenesis pig with 69 edits: three sugar-antigen knockouts (GTKO, β4GalNT2, CMAH), seven human transgenes (CD46, CD55, EPCR, thrombomodulin, CD47, HO-1, A20), and inactivation of porcine endogenous retroviruses. The recipient received induction with anti-thymocyte globulin, anti-CD20 antibody, and a C3 inhibitor. Maintenance was an Fc-silent anti-CD154 agent, tacrolimus, mycophenolate mofetil, and steroids.
The kidney functioned for 271 days, about nine months, before removal for continuous proteinuria. The authors report that the patient regained energy and quality of life, had normal creatinine clearance during the functional period, and needed far less dialysis. The immediate post-operative period was uneventful, with no hyperacute rejection. The authors credit this to the antigen knockouts and human complement regulators, and credit the coagulation-related transgenes with limiting thrombotic microangiopathy. They credit the induction and costimulation-blocking regimen with preventing acute cellular rejection in the first month. They suggest the decline resembled chronic antibody-mediated rejection, with alloantibodies gradually overcoming complement regulation. Macaque studies with similar 3-knockout/7-transgene kidneys showed a median survival of 176 days and a maximum beyond two years, with fibrosis, antibody-mediated rejection, and microangiopathy in long-term survivors.
The review also notes earlier cases from NYU Langone and the University of Alabama at Birmingham using 10-gene-edited United Therapeutics pigs. It reports a 69-year-old woman in China at Xijing Hospital who received a 6-gene-edited Bama miniature pig kidney from ClonOrgan, still functioning at nearly eight months. That result raises the question of whether fewer edits could suffice. The FDA has reportedly approved United Therapeutics- and eGenesis-led trials, which may enroll more than thirty patients.
The authors list several challenges. Intensive immunosuppression raises infection risk, while reducing it because of infection invites rejection. Xenograft scarring appears within months rather than the years seen in allografts. It is not known whether antibody-mediated rejection can be prevented beyond one year, and Columbia is testing thymus-kidney co-transplantation to induce tolerance. Multi-omic analysis of the explanted kidney is proposed to clarify what drives chronic rejection. The authors frame xenotransplantation as a feasible bridge therapy for now, not yet a durable replacement. Because this is a single-case commentary, with some internal inconsistencies, the conclusions should be treated as preliminary.
Principales conclusions
- A 69-edit eGenesis pig kidney functioned in a human for 271 days, a reported record, before removal for persistent proteinuria.
- Knocking out three sugar antigens and adding human complement and coagulation regulators avoided hyperacute rejection in the early post-operative period.
- Failure likely reflects chronic antibody-mediated rejection and microangiopathy, matching macaque data (median 176 days, maximum over two years).
- A Chinese recipient of a 6-gene-edited pig kidney has had nearly eight months of function, suggesting fewer edits might suffice.
- The FDA has reportedly cleared larger xenotransplant trials that may include more than thirty patients across several centers.
Méthodologie
Narrative review and commentary centered on one recently reported pig-to-human kidney xenotransplant, with comparison to non-human primate studies and other clinical cases. No new data, systematic search, or formal quality appraisal is described. Case details are drawn from prior publications and reports.
Limites de l'étude
This is a single-case-based commentary with no new data. It contains internal inconsistencies, including the 10-gene versus 69-edit descriptions, the gene functions attributed to the knockouts, and a questionable comparison with delayed graft function in allotransplantation. The causal attribution of failure to chronic antibody-mediated rejection is speculative without published explant histology, and the cross-case comparison with the 6-gene Chinese case is anecdotal.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :